L’Institut Mérieux has sold its subsidiary ABL Lyon (renamed to Active Biomarkers) to Turenne Santé
Paris – CFI France is pleased to announce that they acted as exclusive financial advisor to l’Institut Mérieux in the sale of its subsidiary ABL Lyon (renamed to Active Biomarkers) to Turenne Santé.
L’Institut Merieux was founded in 1897 in Lyon, is a family holding company dedicated to global public health around the world.
ABL Lyon, now renamed Active Biomarkers, is an integrated bioanalytical laboratory with biomarker and cell-based assay testing capabilities, specialized in well-targeted therapeutic fields such as oncology, infectious diseases, inflammatory pathologies and neurodegenerative diseases.
The company supports multiple biopharmaceutical companies in their clinical research programs (Phases I to IV).
With the support of Turenne Santé, Active Biomarkers will pursue its dynamic growth by gaining new customers. It will also enable to boost significantly its production and R&D capacity, to strengthen its portfolio of proprietary assays, and to evaluate external growth opportunities.
The transaction was announced on 5 November 2020.
Our latest transactions
Software & IT Services
have sold
to
a portfolio company of
Transaction details
Technology field services and support provider Vista Technology Support has been acquired by TRG
Consumer Goods & Retail
has obtained fundraising from
Transaction details
High-end bicycle producer The Rider Firm has obtained fundraising from Santander
Software & IT Services
has raised growth capital from
Transaction details
Digital Pills, an Italian Data & AI consulting company, has sold a minority stake to Equiter, raising funds for its future growth
